ZA200400837B - Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. - Google Patents
Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. Download PDFInfo
- Publication number
- ZA200400837B ZA200400837B ZA200400837A ZA200400837A ZA200400837B ZA 200400837 B ZA200400837 B ZA 200400837B ZA 200400837 A ZA200400837 A ZA 200400837A ZA 200400837 A ZA200400837 A ZA 200400837A ZA 200400837 B ZA200400837 B ZA 200400837B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- surgery
- injury
- lasik
- ait
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 30
- 238000001356 surgical procedure Methods 0.000 title claims description 30
- 210000005036 nerve Anatomy 0.000 title claims description 25
- 208000014674 injury Diseases 0.000 title claims description 16
- 230000006378 damage Effects 0.000 title claims description 15
- 208000027418 Wounds and injury Diseases 0.000 title claims description 13
- 230000008733 trauma Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 27
- 210000002569 neuron Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 230000014511 neuron projection development Effects 0.000 claims description 17
- 230000008929 regeneration Effects 0.000 claims description 16
- 238000011069 regeneration method Methods 0.000 claims description 16
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 11
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 10
- 206010013774 Dry eye Diseases 0.000 claims description 10
- 210000004087 cornea Anatomy 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 9
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims description 5
- 229960004135 idebenone Drugs 0.000 claims description 5
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 claims description 4
- -1 CB-1093 Chemical compound 0.000 claims description 4
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims 6
- 229950005455 eliprodil Drugs 0.000 claims 6
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims 3
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 claims 3
- 229960002934 propentofylline Drugs 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 27
- 102000007072 Nerve Growth Factors Human genes 0.000 description 21
- 239000003900 neurotrophic factor Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000003994 retinal ganglion cell Anatomy 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 description 4
- 101150111783 NTRK1 gene Proteins 0.000 description 4
- 102100033857 Neurotrophin-4 Human genes 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000013010 irrigating solution Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108090000742 Neurotrophin 3 Proteins 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- 101150056950 Ntrk2 gene Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940021384 salt irrigating solution Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010061213 Iatrogenic injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940035183 bion tears Drugs 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940036266 tears naturale Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000015533 trkA Receptor Human genes 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31565201P | 2001-08-29 | 2001-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200400837B true ZA200400837B (en) | 2005-02-02 |
Family
ID=23225436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200400837A ZA200400837B (en) | 2001-08-29 | 2004-02-02 | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1420791A4 (es) |
| JP (1) | JP2005502678A (es) |
| CN (1) | CN1549718A (es) |
| AR (1) | AR036194A1 (es) |
| BR (1) | BR0212151A (es) |
| CA (1) | CA2455896A1 (es) |
| MX (1) | MXPA04001255A (es) |
| PL (1) | PL368565A1 (es) |
| WO (1) | WO2003020281A1 (es) |
| ZA (1) | ZA200400837B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004091662A1 (ja) * | 2003-04-18 | 2004-10-28 | Senju Pharmaceutical Co. Ltd. | 角膜知覚回復剤 |
| ES2234428B1 (es) * | 2003-12-09 | 2006-11-01 | Universidad Miguel Hernandez | Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva. |
| CN1997381B (zh) * | 2004-04-23 | 2011-06-08 | 千寿制药株式会社 | 含有pacap及其衍生物的角膜神经突形成促进剂 |
| JP4932480B2 (ja) * | 2004-06-03 | 2012-05-16 | 千寿製薬株式会社 | アミド化合物を含有する角膜知覚回復剤 |
| US20090082455A1 (en) | 2005-03-15 | 2009-03-26 | Ono Pharmaceutical Co. Lted | Therapeutic agent for ophthalmic disease |
| CN113350326B (zh) * | 2021-07-28 | 2023-03-17 | 爱尔眼科医院集团股份有限公司 | 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166317A (en) * | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
| FR2672213B1 (fr) * | 1991-02-05 | 1995-03-10 | Sanofi Sa | Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres. |
| US5767079A (en) * | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
| US5604244A (en) * | 1995-06-07 | 1997-02-18 | Alcon Laboratories, Inc. | Intraocular irrigating solution containing a polyamine antagonist |
| TWI246421B (en) * | 1998-12-03 | 2006-01-01 | Alcon Mfg Ltd | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| WO2001085152A2 (en) * | 2000-05-10 | 2001-11-15 | Alcon, Inc. | R-eliprodil for treating glaucoma |
-
2002
- 2002-07-23 BR BR0212151-4A patent/BR0212151A/pt not_active Application Discontinuation
- 2002-07-23 MX MXPA04001255A patent/MXPA04001255A/es not_active Application Discontinuation
- 2002-07-23 CA CA002455896A patent/CA2455896A1/en not_active Abandoned
- 2002-07-23 EP EP02756710A patent/EP1420791A4/en not_active Withdrawn
- 2002-07-23 JP JP2003524588A patent/JP2005502678A/ja not_active Withdrawn
- 2002-07-23 CN CNA028168682A patent/CN1549718A/zh active Pending
- 2002-07-23 WO PCT/US2002/023871 patent/WO2003020281A1/en not_active Application Discontinuation
- 2002-07-23 PL PL02368565A patent/PL368565A1/xx unknown
- 2002-07-30 AR ARP020102872A patent/AR036194A1/es unknown
-
2004
- 2004-02-02 ZA ZA200400837A patent/ZA200400837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1420791A4 (en) | 2004-09-15 |
| EP1420791A1 (en) | 2004-05-26 |
| MXPA04001255A (es) | 2004-05-27 |
| AR036194A1 (es) | 2004-08-18 |
| JP2005502678A (ja) | 2005-01-27 |
| CN1549718A (zh) | 2004-11-24 |
| BR0212151A (pt) | 2004-08-24 |
| WO2003020281A1 (en) | 2003-03-13 |
| CA2455896A1 (en) | 2003-03-13 |
| PL368565A1 (en) | 2005-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010017541A2 (en) | Compositions and methods for treatment of neurodegenerative disease | |
| DE60206289T2 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| JP2009001591A (ja) | 緑内障治療用のデプレニル化合物 | |
| DE69924284T2 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
| ZA200400837B (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma. | |
| RU2432948C2 (ru) | Применение активаторов растворимой гуанилатциклазы для лечения нарушений кровоснабжения | |
| JP2016026229A (ja) | Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用 | |
| US20040162315A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma | |
| RU2134107C1 (ru) | Препарат "гистохром" для лечения воспалительных заболеваний сетчатки и роговицы глаз | |
| WO2000021531A1 (fr) | Medicaments pour maladies oculaires | |
| LANGHAM et al. | The action of protriptyline on adrenergic mechanisms in rabbit, primate and human eyes | |
| CN105935443A (zh) | 一种治疗糖尿病性白内障的药物组合物 | |
| AU2002322700A1 (en) | Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma | |
| US20050203121A1 (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases | |
| JP2004331502A (ja) | 視神経細胞保護剤 | |
| RU2224519C2 (ru) | Антиоксидантное и стимулирующее рост нервных клеток средство | |
| Grehn et al. | Neuroprotection in Glaucoma | |
| US8106096B2 (en) | Compositions and methods for treatment of optic nerve diseases | |
| JP4393863B2 (ja) | 視神経細胞保護剤 | |
| WO2001056606A1 (fr) | Remedes pour troubles ophtalmiques | |
| JP2023042650A (ja) | 眼科用剤 | |
| CN113350326A (zh) | 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用 | |
| MXPA01002895A (es) | Uso de estimuladores del factor neutrofico para el tratamiento de enfermedades oftalmicas neurodegenerativas | |
| KR20070019001A (ko) | 안구 신경퇴행성 질환의 치료를 위한 신경성 인자 자극제 | |
| WO2006021166A1 (de) | Kombinationstherapie mit procain |